Focuses on developing novel therapeutics for the treatment of autoimmune diseases and cancer.
ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company specializing in immunology, committed to developing transformative treatments aimed at improving patient outcomes. Established in 2010 and based in Singapore, the company focuses on advancing a diverse clinical portfolio designed to address significant medical challenges.
At the forefront of ASLAN Pharmaceuticals' innovation is ASLAN004, a monoclonal therapy currently undergoing development for atopic dermatitis and other immunology-related indications. Additionally, the company is progressing ASLAN003, a small-molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at treating autoimmune conditions. ASLAN Pharmaceuticals collaborates through strategic partnerships, including joint ventures with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., focusing on immuno-oncology therapeutics that target the AhR pathway.
Through collaborations with industry leaders such as Almirall, Array BioPharma, and CSL Limited, ASLAN Pharmaceuticals leverages collective expertise to drive the development and commercialization of novel therapies. With a dedication to scientific excellence and global reach, the company continues to expand its footprint in the biopharmaceutical sector, advancing therapies that hold promise for patients worldwide.